Request Demo

Last update 08 May 2025

Rumbrin

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action

inhibitors

Mechanism

Lipid peroxidation inhibitors

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Kirin Holdings Co., Ltd.

Active Organization-

Inactive Organization

Kirin Holdings Co., Ltd.

License Organization-

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC20H20ClNO3

InChIKeyTUFFAFAPFQNIRB-KDZWSXRISA-N

CAS Registry150206-14-7

100 Clinical Results associated with Rumbrin

100 Translational Medicine associated with Rumbrin

100 Patents (Medical) associated with Rumbrin

Literatures (Medical) associated with Rumbrin

01 Oct 2023·Cancer science

Identification of compounds that preferentially suppress the growth of T-cell acute lymphoblastic leukemia-derived cells.

Article

Author: Doki, Noriko ; Seki, Fumiya ; Hachiro, Yoshifumi ; Kanda, Risa ; Hara, Takahiko ; Yagi, Takuya ; Nuriya, Hideko ; Maki, Shojiro A ; Goyama, Susumu ; Kitamura, Toshio ; Miyashita, Kazuya ; Kagaya, Noritaka ; Shin-Ya, Kazuo ; Nakata, Chihiro ; Kitada, Nobuo ; Hoyano, Shota ; Higashi, Tomoya ; Najima, Yuho ; Takechi, Azusa ; Yoshida, Chihiro ; Kobayashi, Takeshi ; Toya, Takashi ; Tanegashima, Kosuke

T-cell acute lymphoblastic leukemia (T-ALL) is one of the most frequently occurring cancers in children and is associated with a poor prognosis. Here, we performed large-scale screening of natural compound libraries to identify potential drugs against T-ALL. We identified three low-molecular-weight compounds (auxarconjugatin-B, rumbrin, and lavendamycin) that inhibited the proliferation of the T-ALL cell line CCRF-CEM, but not that of the B lymphoma cell line Raji in a low concentration range. Among them, auxarconjugatin-B and rumbrin commonly contained a polyenyl 3-chloropyrrol in their chemical structure, therefore we chose auxarconjugatin-B for further analyses. Auxarconjugatin-B suppressed the in vitro growth of five human T-ALL cell lines and two T-ALL patient-derived cells, but not that of adult T-cell leukemia patient-derived cells. Cultured normal T cells were several-fold resistant to auxarconjugatin-B. Auxarconjugatin-B and its synthetic analogue Ra#37 depolarized the mitochondrial membrane potential of CCRF-CEM cells within 3 h of treatment. These compounds are promising seeds for developing novel anti-T-ALL drugs.

01 Oct 2023·Bioorganic & Medicinal Chemistry Letters

Synthesis and anti-tumor activities in human leukemia-derived cells of polyenylpyrroles with a methyl group at the conjugated polyene terminus

Article

Author: Obata, Rika ; Hachiro, Yoshifumi ; Higashi, Tomoya ; Miyashita, Kazuya ; Hirano, Takashi ; Kitada, Nobuo ; Takechi, Azusa ; Yagi, Takuya ; Yoshida, Chihiro ; Hara, Takahiko ; Nakata, Chihiro ; Maki, Shojiro A

To develop novel drugs for treating T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML) which are highly malignant hematological tumors, a series of analogs having a polyenylpyrrole structure of natural compounds (rumbrin and auxarconjugatin B) were synthesized and investigated their structure-activity relationships (SAR) of in vitro anti-T-ALL and anti-AML activities. We obtained three findings: (1) introduction of a methyl group at the conjugated polyene terminus enhanced anti-T-ALL activity, (2) analogs with a 3-chloropyrrole moiety had even higher selectivity for T-ALL cells, and (3) some analogs were effective against AML-derived cells. Among the studied compounds, 3-chloro-2-(8-ethoxycarbonylnona-1,3,5,7-tetraenyl) pyrrole 4e was the most promising candidate of T-ALL- and AML-treating drug. This study provides useful structural information for designing novel drugs treating T-ALL and AML.

01 Dec 2022·The Journal of Antibiotics

Plant growth-promoting and antimicrobial chloropyrroles from a rare actinomycete of the genus Catellatospora

Article

Author: Hayakawa, Masayuki ; Igarashi, Yasuhiro ; Liu, Chang ; Zhang, Zhiwei ; Oku, Naoya ; Yamamura, Hideki

Two new chloropyrroles, designated catellatopyrroles A (1) and B (2), along with 2-(2'-hydroxybenzoyl)pyrrole (3), were isolated from a culture extract of an actinomycete of the genus Catellatospora. The structures of 1-3 were elucidated through interpretation of NMR and MS data. Compounds 1 and 2 are the first chloropyrroles substituted by an aliphatic acyl group at the 5-position. Compounds 1-3 promoted root elongation of germinated lettuce seeds at 1-10 μM. While all compounds inhibited the growth of Gram-positive bacteria, activity against Gram-negative bacterium Rhizobium radiobacter and yeasts Candida albicans and Saccharomyces cerevisiae was varied. Compounds 1 and 2 were moderately cytotoxic against P388 cells.

100 Deals associated with Rumbrin

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Rumbrin

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation